Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02052635 · ClinicalTrials.gov registry record · Phase 4
Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.
A Phase 4 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT02052635 is a Phase 4 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 34 participants.
The verdict
NCT02052635, a Phase 4 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if ticagrelor is as effective as clopidogrel in rate of onset and degree of platelet inhibition for patients with non-ST elevation of acute coronary syndrome (NSTE-ACS) undergoing ad hoc percutaneous coronary intervention (PCI) with bivalirudin.
Interventions
- DRUG clopidogrel
- DRUG ticagrelor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02052635
The ClinicalTrials.gov registry entry for NCT02052635 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which clopidogrel is the first listed.
NCT02052635 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02052635 about?
NCT02052635 is a clinical study titled "Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.". The purpose of this study is to determine if ticagrelor is as effective as clopidogrel in rate of onset and degree of platelet inhibition for patients with non-ST elevation of acute coronary syndrome (NSTE-ACS) undergoing ad hoc percutaneous coronary intervention (PCI) with bivalirudin.
What is the current status of trial NCT02052635?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2014-09. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02052635?
The interventions under investigation include: clopidogrel (DRUG), ticagrelor (DRUG).
Who is sponsoring clinical trial NCT02052635?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.